Most Read Articles
21 Nov 2020
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
6 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

3 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.

Infliximab use tied to reversal of clotting abnormalities in IBD patients

06 Oct 2020

Treatment with infliximab to control inflammation effectively reduces parameters that are associated with a higher risk of venous thromboembolism in patients with inflammatory bowel disease (IBD), results of a study have shown.

Sixty-two patients with active IBD initiating infliximab, vedolizumab, or methylprednisolone and 22 health controls were included in this prospective study. The investigators collected plasma before (w0) and after induction therapy (w14).

Clot lysis assay was used to determine amplitude (marker for clot intensity), time to peak (Tmax; marker for clot formation rate), area under the curve (AUC; global marker for coagulation/fibrinolysis), and 50-percent clot lysis time (50%CLT; marker for fibrinolytic capacity). Plasminogen activator inhibitor-1 (PAI-1) and fibronectin were measured using ELISA. Clinical remission was assessed at w14.

AUC, amplitude and 50%CLT at baseline were significantly higher in IBD patients than in healthy controls. In 34 remitters, AUC (165 percent vs 97 percent; p=0.001), amplitude (119 percent vs 95 percent; p=0.002), and 50%CLT (122 percent vs 100 percent; p=0.001) were reduced significantly and even normalized to healthy control level.

An inverse association was found between vedolizumab trough concentration and fibronectin concentration (r, –0.732; p=0.002). The increase in Tmax for infliximab-treated remitters showed a significant difference from the decrease in Tmax for vedolizumab-treated remitters (p=0.028). Moreover, the 50%CLT increased (p=0.038) when remitters were concomitantly treated with methylprednisolone.

“Active IBD represent an independent risk factor for venous thromboembolism,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
21 Nov 2020
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
6 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

3 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.